Subtitle: Market Intelligence, Preclinical Progress, and High-Purity Reagents for Platinum Resistance & Targeted Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ASNA1/GET3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ASNA1 WT & ATPase-Dead Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW confirmed. |
View ASNA1 Products |
| Gene Delivery | ASNA1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View ASNA1 Products |
| Benchmark Ab | Anti-ASNA1 (Recombinant Rabbit mAb) Research-grade positive control for WB/IHC/IF detection. |
View ASNA1 Products |
| Validator | ASNA1 siRNA Set For knockdown and specificity verification. |
View ASNA1 Products |
| Related Target A | GET1 (WRB) ER membrane receptor for the GET pathway; essential for PPI assays. |
View GET1 Products |
| Related Target B | SLC31A1 (CTR1) Copper/platinum import transporter; convergent resistance node. |
View SLC31A1 Products |
| Related Target C | GET4 Direct binding partner in the GET pathway (facilitates TA protein transfer). |
View GET4 Products |
| Related Target D | WRB (redundant with GET1, but also listed as separate receptor) | View WRB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Need for Catalytically Inactive Controls in ATPase Assays | ASNA1 E285Q / D57N Mutant Proteins, Sequence Verified, >95% purity |
| Biophysical Grade Purity for Fragment Screening & Crystallography | Endotoxin <1 EU/ug; Monodisperse formulation; Theoretical MW confirmed |
| Orthogonal Target Validation (Genetic vs Pharmacological) | Validated siRNA + Benchmark Antibody included |
| Cellular Platinum Resistance Modeling | Full-length ORF Lentivirus for stable overexpression in drug-sensitive backgrounds |
| ATPase Assay Background Noise | High purity (>95%) recombinant protein, Endotoxin <1EU/ug, isolated without co-purifying ATPases |
| Protein-Protein Interaction (PPI) Validation | Theoretical MW strictly verified; native folding preserved for ASNA1-GET4/GET5 SPR/BLI binding assays |
Live ASNA1/GET3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ASNA1/GET3 therapeutics is transitioning from mechanistic biology to structured drug discovery. As a key ATPase driving insertion of tail-anchored (TA) proteins into the ER and an oxidative stress chaperone, ASNA1 is highly implicated in platinum-based chemotherapy resistance (e.g., cisplatin). Emerging pipelines focus on small-molecule-mediated sensitization, allosteric pockets, and protein-protein interaction disruptors that destabilize the GET complex. Beyond oncology, ASNA1's role in insulin secretion opens potential in metabolic disease. As first-generation resistance modulators advance through preclinical development, the next wave targets both ATPase activity and GET pathway protein interactions.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic consortia & emerging biotech | Platinum-resistant ovarian, lung, gastric cancers; refractory solid tumors | ATPase & Thermal Shift Assay (Need WT + Mutant Proteins) |
| PROTAC / Degrader | Early-stage discovery programs | Solid tumors (pancreatic, melanoma) | Cellular degradation & rescue (Need Lentivirus + siRNA) |
| siRNA / Antisense / Genetic Sensitization | Functional genomics groups; early discovery | Cisplatin-resistant ovarian cancer; broad oncology panels | Knockdown validation (Need high-specificity siRNA) |
Key Mutations & Functional Controls
Mutations in ASNA1 are associated with CMD2H (dilated cardiomyopathy type 2H). Key variants include:
- W289 (pathogenic)
- Q305-Q348 deletion (in cis with W289)
- Catalytic dead mutants E285Q and D57N (used as negative controls in ATPase assays)
TarMart provides recombinant proteins with these mutations for mechanism-of-action studies.
Strategic Assay Recommendations
- ATPase Activity Inhibition – Use malachite green or ADP-Glo with WT and mutant proteins.
- Differential Scanning Fluorimetry (DSF) – For fragment screening.
- SPR/BLI – For PPI disruption (ASNA1 with GET1, GET4, WRB).
- Cellular rescue – siRNA knockdown + lentiviral overexpression in cisplatin-resistant cells.
- Degradation assays – For PROTAC molecules, use anti-ASNA1 antibody.
TarMart's product suite supports each step with high-purity proteins, validated siRNA, lentivirus, and antibodies.